Regarding "Does simvastatin save lives; If so, when and in whom?"

Journal of Vascular Surgery

Volumn 47, Issue 4, 2008, Pages 900-901

  Vos, Eddie ^a   Mascitelli, Luca ^b   Rose, Colin P ^c  

^a Sutton ^*  (Canada)

^b Comando Brigata alpina Julia ^*  (Italy)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ARTERY DISEASE; CARDIOVASCULAR RISK; DEATH; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; REVASCULARIZATION; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; FEMALE; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; SEX FACTORS; SIMVASTATIN;

EID: 41149139914     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.10.065     Document Type: Letter

References (6)

1. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007) 645-654
2. Collins R., Keech A., Peto R., Sleight P., Kjekshus J., Wilhelmsen L., et al. Cholesterol and total mortality: need for larger trials. BMJ 304 (1992) 1689
3. http://www.ctsu.ox.ac.uk/pressreleases/2001-11-13/life-saver-world-slargest-cholesterol-lowering-trial-reveals-massive-benefits-for-high-riskpatients/?searchterm=merck (accessed Oct 19, 2007)
4. Boden W.E., O'Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J., et al., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
5. Strandberg T.E., Pyörälä K., Cook T.J., Wilhelmsen L., Faergeman O., Thorgeirsson G., et al., 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 364 (2004) 771-777
6. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID). Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357